Shots:

• The approval is based on the positive outcomes of a clinical trial assessing Itolizumab for its safety and efficacy in preventing CRS in moderate to severe ARDS patients due to COVID-19 at multiple hospitals in Mumbai and New Delhi  
• The study met its 1EP with a reduction in mortality rates and other 2EPs for efficacy and biomarkers were also achieved
• ALZUMAb (itolizumab- 25mg/5mL) is an anti-CD6 IgG1 mAb launched for the treatment of chronic plaque psoriasis in India in 2013- manufactured and formulated IV injection at Biocon’s bio-manufacturing facility at Biocon Park- Bengaluru

Click here to read full press release/ article | Ref: Biocon | Image: Behnace